Savannah Chrisley just launched a telehealth company geared toward women, selling them injectable weight loss medication and more. We wanted to know who is really behind this latest venture, is it a doctor? no, it is not. It is a former lawyer and serial entrepreneur with a checkered past. The goodgirlrx.com website lists a residential home address as its company headquarters, a home owned by Rory Cutaia, the CEO of Verb Technology…. and partner of Savannah Chrisley – so who is Rory Cutaia and what do the two of them know about medicine.

Introduction:Verb Technology Company, Inc. (NASDAQ: VERB), backed financially by Corinthian Capital and led by CEO Rory J. Cutaia, finds itself embroiled in escalating controversies. Recent revelations of Corinthian’s 2019 SEC sanctions, persistent allegations of stock manipulation, and a contentious telemedicine venture with Savannah Chrisley—a reality star previously linked to consumer fraud—point to systemic governance failures and questionable strategic decisions.

Corinthian Capital’s Troubling Past:In 2019, Corinthian Capital faced SEC sanctions, resulting in $140,000 in penalties due to significant regulatory violations. Corinthian misappropriated around $1.2 million from its Corinthian Equity Fund II (CEF 2), diverting these funds to pay unrelated operating expenses, including payroll and loans, directly breaching investor agreements. The firm also improperly billed investors $588,394 and consistently violated custody regulations by delaying audits from 2013–2015. CFO David Tahan and CEO Peter Van Raalte were implicated, with Van Raalte personally fined for supervisory neglect.

Though CEO Rory J. Cutaia was not directly named, Corinthian’s questionable governance has undeniably cast a shadow over Verb’s operations. Securities attorney Emily Torres notes, “Corinthian’s historical misconduct has shaped Verb’s troubling legal trajectory.”

Verb’s Mounting Legal Challenges:Verb Technology’s recent history is plagued by legal controversies:

• 2020 Class Action Settlement: Investors accused Verb of inflating stock prices with exaggerated claims about partnerships with major corporations like Microsoft and Adobe, leading to a $2.25 million SEC fine.
• 2023 Stock Manipulation Allegations: Recent class-action lawsuits allege “pump-and-dump” schemes by Verb and Corinthian, exacerbating investor skepticism and resulting in a stock collapse of approximately 80% since 2020.

Cutaia’s earlier business, Tel-Save, previously faced SEC scrutiny for aggressive accounting practices in the 1990s, further raising concerns about his leadership style.

The Savannah Chrisley Connection:Verb’s pivot to telemedicine with the GoodGirlRx.com platform, featuring reality TV personality Savannah Chrisley, further complicates its credibility. Chrisley’s reputation is marred by past scandals:

• Chrisley Box Scam: In 2020, Chrisley promoted a luxury subscription box service accused of defrauding consumers, leading to lawsuits and FTC investigations.
• Sassy by Savannah: Her makeup brand faced criticism for poor product quality and delayed shipments, labeled by many consumers as a blatant “cash grab.”

Healthcare analyst Dr. Lisa Nguyen remarked, “Partnering with Chrisley significantly undermines GoodGirlRx’s credibility, raising substantial regulatory and ethical concerns.”

GoodGirlRx.com and Telehealth Controversies:GoodGirlRx.com aims to capitalize on the booming telehealth weight-loss market, primarily by offering injectable medications like semaglutide, commonly sold under brand names such as Ozempic and Wegovy. While the telehealth model promises convenience, its growth has been controversial:

• Safety and Oversight Concerns: Critics argue telemedicine platforms lack adequate medical supervision, potentially leading to overprescription and increased health risks, including severe gastrointestinal side effects.
• Compounded Medications: Due to high costs and supply issues with brand-name semaglutide, many telehealth providers offer compounded alternatives, which are not FDA-approved. The FDA has reported adverse health incidents linked to these compounded products.
• Regulatory and Ethical Scrutiny: Telemedicine firms marketing compounded semaglutide have faced backlash and regulatory scrutiny, notably Hims & Hers, criticized for misleading advertisements.
• Equity Issues: Telehealth weight-loss treatments are expensive and often exclude economically disadvantaged patients, reinforcing health inequities and potentially diverting attention from essential lifestyle changes.

These controversies suggest Verb’s move into telehealth could exacerbate its existing ethical and compliance challenges.

Financial Instability and Market Reactions:Verb’s recent financial results show a concerning 22% revenue decline year-over-year as of Q1 2024, highlighting investor skepticism regarding its healthcare pivot. Analyst Kyle Peterson stated, “Corinthian’s past abuses now cast serious doubt over Verb’s future direction and stability.”

Conclusion:Verb Technologies’ ongoing troubles—from SEC sanctions against its financial backer, Corinthian Capital, and persistent allegations of misconduct, to risky ventures with controversial figures like Savannah Chrisley—paint a picture of systemic risk and corporate recklessness. Without immediate transparency and reform, Verb risks further deterioration, potentially leaving investors and customers vulnerable to continued instability and ethical compromises.

This investigative report incorporates SEC filings, court documents, public records, and industry analyses.